Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 2% – Here’s Why

Jasper Therapeutics, Inc. (NASDAQ:JSPR)’s share price was down 2% during mid-day trading on Tuesday . The stock traded as low as $1.41 and last traded at $1.44. Approximately 264,139 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 966,267 shares. The stock had previously closed at $1.47.

Analyst Upgrades and Downgrades

Several research firms have weighed in on JSPR. Rodman & Renshaw began coverage on Jasper Therapeutics in a research note on Tuesday, January 13th. They set a “buy” rating and a $17.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $19.88.

Jasper Therapeutics Stock Performance

The company has a market capitalization of $40.29 million, a PE ratio of -0.24 and a beta of 3.08. The stock has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $2.22.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.12). Sell-side analysts predict that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of large investors have recently bought and sold shares of JSPR. Acadian Asset Management LLC bought a new position in Jasper Therapeutics during the first quarter valued at about $46,000. Marex Group plc bought a new stake in shares of Jasper Therapeutics during the 2nd quarter worth about $74,000. Engineers Gate Manager LP bought a new stake in shares of Jasper Therapeutics during the 2nd quarter worth about $78,000. Voleon Capital Management LP acquired a new position in shares of Jasper Therapeutics during the 3rd quarter valued at about $50,000. Finally, XTX Topco Ltd bought a new position in shares of Jasper Therapeutics in the 2nd quarter valued at approximately $152,000. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.